These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28284377)

  • 1. Treatment of Renal Fibrosis-Turning Challenges into Opportunities.
    Klinkhammer BM; Goldschmeding R; Floege J; Boor P
    Adv Chronic Kidney Dis; 2017 Mar; 24(2):117-129. PubMed ID: 28284377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential approaches to reverse or repair renal fibrosis.
    Tampe D; Zeisberg M
    Nat Rev Nephrol; 2014 Apr; 10(4):226-37. PubMed ID: 24514753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats.
    Chen JF; Ni HF; Pan MM; Liu H; Xu M; Zhang MH; Liu BC
    Am J Physiol Renal Physiol; 2013 Mar; 304(6):F676-85. PubMed ID: 23152296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targets for treating fibrotic kidney diseases.
    Lee SY; Kim SI; Choi ME
    Transl Res; 2015 Apr; 165(4):512-30. PubMed ID: 25176603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A perspective on anti-CCN2 therapy for chronic kidney disease.
    Falke LL; Goldschmeding R; Nguyen TQ
    Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i30-i37. PubMed ID: 24493868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.
    Chen L; Yang T; Lu DW; Zhao H; Feng YL; Chen H; Chen DQ; Vaziri ND; Zhao YY
    Biomed Pharmacother; 2018 May; 101():670-681. PubMed ID: 29518614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between extracellular matrix components and cellular and molecular mechanisms in kidney fibrosis.
    Rayego-Mateos S; Campillo S; Rodrigues-Diez RR; Tejera-Muñoz A; Marquez-Exposito L; Goldschmeding R; Rodríguez-Puyol D; Calleros L; Ruiz-Ortega M
    Clin Sci (Lond); 2021 Aug; 135(16):1999-2029. PubMed ID: 34427291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targets for treatment of kidney fibrosis.
    Chuang PY; Menon MC; He JC
    J Mol Med (Berl); 2013 May; 91(5):549-59. PubMed ID: 23179685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting TGF-β Signaling in Kidney Fibrosis.
    Isaka Y
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30150520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Therapies for the Treatment of Renal Fibrosis.
    Liu F; Zhuang S
    Adv Exp Med Biol; 2019; 1165():625-659. PubMed ID: 31399988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal fibrosis: Recent translational aspects.
    François H; Chatziantoniou C
    Matrix Biol; 2018 Aug; 68-69():318-332. PubMed ID: 29292218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression in chronic kidney disease.
    Eddy AA
    Adv Chronic Kidney Dis; 2005 Oct; 12(4):353-65. PubMed ID: 16198274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Targets for Therapy of Renal Fibrosis.
    Prakoura N; Hadchouel J; Chatziantoniou C
    J Histochem Cytochem; 2019 Sep; 67(9):701-715. PubMed ID: 31116064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Magnetic Resonance Imaging Assessment of Renal Fibrosis.
    Li J; An C; Kang L; Mitch WE; Wang Y
    Adv Chronic Kidney Dis; 2017 May; 24(3):150-153. PubMed ID: 28501077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?
    Muñoz-Félix JM; González-Núñez M; Martínez-Salgado C; López-Novoa JM
    Pharmacol Ther; 2015 Dec; 156():44-58. PubMed ID: 26493350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel targets of antifibrotic and anti-inflammatory treatment in CKD.
    Declèves AE; Sharma K
    Nat Rev Nephrol; 2014 May; 10(5):257-67. PubMed ID: 24662433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling.
    Andrikopoulos P; Kieswich J; Pacheco S; Nadarajah L; Harwood SM; O'Riordan CE; Thiemermann C; Yaqoob MM
    J Am Soc Nephrol; 2019 Jan; 30(1):33-49. PubMed ID: 30530834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats.
    Thakur R; Sharma A; Lingaraju MC; Begum J; Kumar D; Mathesh K; Kumar P; Singh TU; Kumar D
    Biomed Pharmacother; 2018 May; 101():972-980. PubMed ID: 29635907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease growth factors in renal fibrosis.
    Boor P; Floege J
    Clin Exp Pharmacol Physiol; 2011 Jul; 38(7):441-50. PubMed ID: 21276040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model.
    Li G; Ren J; Hu Q; Deng Y; Chen G; Guo K; Li R; Li Y; Wu L; Wang G; Gu G; Li J
    Biochem Pharmacol; 2016 Oct; 117():57-67. PubMed ID: 27498142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.